Early Rhythm Control Therapy for Atrial Fibrillation Unchanged by Diabetes, Obesity
Despite obesity’s well-known influence on AF recurrence, neither comorbidity has a significant influence on outcomes from early rhythm control therapy.
Related Articles
Repeat Pulse Field Ablations for Atrial Fibrillation are Safe and Efficacious
Recent research has shown long-lasting freedom of documented AF and atrial tachycardia.
Psoriasis Linked to Increased Cardiovascular, Suicide Related Mortality Risk
Findings highlight an association between psoriasis and risks of all-cause, cardiovascular, infection-related, and suicide mortality.
HCPLive Five – Dermatology Updates at DERM 2025 NP/PA Conference
Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key dermatology updates from the DERM2025…
Esketamine Rapidly Improves Sleep in Treatment-Resistant Depression
Phase 4 data reveal esketamine outperforms standard antidepressants in reducing insomnia and boosting next-day well-being in patients with TRD.
HFSA and ASPC Release Statement on Shifting to Prevention in Heart Failure
The 2 organizations released a joint statement on challenging the common view of HF as an inevitability and prioritizing preventive measures.
From Guidelines to the Clinic: Applying Precision Medicine in COPD and Asthma
Discover how precision medicine and advanced biologics are revolutionizing COPD and asthma management, enhancing patient outcomes and quality of life.
Targeted Education for Standardized Photo Documentation May Improve Hair Loss Care
Providing nurses and MAs with an educational video on standardized hair loss photo techniques increased the quantity and quality of documented pictures.
Real-World Study Affirms Baricitinib’s Efficacy for Alopecia Areata
In a Chinese cohort, baricitinib achieved high hair regrowth rates in alopecia areata, totalis, universalis, and eyebrow/eyelash loss, with no serious adverse events.
Phase 3 Findings Suggest Icotrokinra Effective in Adults, Adolescents with Psoriasis
These data from the ICONIC-LEAD study were presented at DERM 2025, highlighting the efficacy and safety of icotrokinra in patients with psoriasis.
FDA, Sun Pharmaceuticals Issue National Recall of Spironolactone 25 mg Tablets
Over 11,000 bottles have been voluntarily recalled in response to a consumer complaint of a foreign substance inside a tablet, later identified as aluminum.